Skip to main content

Table 1 Characteristics of Analyzed Population at Year 1 (n = 5,307) with 628 deaths at up to 15 years of follow-up

From: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

  N % Person-Years of Follow-up Deaths per 1,000 Person Years
Sex     
   Female 1993 37.6 24,764 8.3
   Male 3314 62.4 40,708 10.4
Age Group, Years     
   35-39 522 9.8 6,610 3.8
   40-49 2099 39.6 26,350 5.5
   50-59 2494 47.0 30,267 13.7
   60+ 192 3.6 2,245 18.7
Body Mass Index, kg/m2     
   < 25 2528 47.6 31,168 9.5
   25- 30 2082 39.2 25,791 9.1
   > = 30 697 13.1 8,513 11.5
Education, Years     
   < 12 632 11.9 7,720 13.0
   12 1592 30.0 19,629 10.0
   > 12 3083 58.1 38,123 8.7
Race     
   White 5108 96.3 63,117 9.2
   Black 199 3.7 2,355 20.8
Smoking Status     
   Former 1439 27.1 17,966 7.0
   Intermittent 628 11.8 7,752 9.5
   Current 3240 61.1 39,754 10.8
Randomization Group     
   Intervention, Ipratroprium 1793 33.8 22,141 8.9
   Intervention, Placebo 1785 33.6 22,108 9.0
   Control 1729 32.6 21,223 11.0
Stage (pre-bronchodilator)*     
   Stage 3 or 4 67 1.3 799 15.0
   Stage 2 3432 64.7 42,208 10.7
   Stage 1 1354 25.5 16,852 7.3
   Restricted 69 1.3 840 9.5
   Normal 385 7.3 4,773 6.7
Stage (post-bronchodilator)*     
   Stage 3 or 4 19 0.4 224 13.4
   Stage 2 2540 47.9 31,126 12.1
   Stage 1 1565 29.5 19,386 7.8
   Restricted 125 2.4 1,487 12.1
   Normal 1058 19.9 13,249 5.8
  1. *Modified chronic obstructive pulmonary disease stage, as defined in methods